NEUROSENSE THERAPEUTICS LTD. TO PARTICIPATE IN RENMARK'S VIRTUAL NON-DEAL ROADSHOW SERIES ON, TUESDAY, MARCH 21 AND TUESDAY, MARCH 28, 2023

Rhea-AI Summary

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) will participate in Renmark Financial Communications' Virtual Non-Deal Roadshow Series on March 21, 2023, at 11:00 AM PST, and March 28, 2023, at 10:00 AM EST. The sessions will feature CEO Alon Ben-Noon and VP Nedira Salzman-Frenkel, focusing on the latest investor presentation and a live Q&A. Interested investors can register for the events, with limited spots available. Replays will be accessible later on the company's investor website. NeuroSense is dedicated to developing treatments for neurodegenerative diseases, addressing significant unmet medical needs in this area.

News Market Reaction – NRSN

+2.87%

+2.87% Session move

In the trading session that priced this news, NRSN gained 2.87%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., March 14, 2023 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), announced today that they will be participating in Renmark Financial Communications Inc.'s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Tuesday, March 21, 2023, at 11:00 AM PST and Tuesday, March 28, 2023 at 10:00 AM EST. NeuroSense Therapeutics Ltd. welcomes stakeholders, investors, and other individual followers to register and attend these live events.

The presentations will feature Alon Ben-Noon, Chief Executive Officer, and Nedira Salzman-Frenkel, VP of Business Development. Topics to be covered will include the latest investor presentation followed by a live Q&A. Investors interested in participating in either of these events will need to register using the links below. As a reminder, registration for the live events may be limited but access to the replay after the events will be on The Company's Investor website.

REGISTER HERE:

Tuesday, March 21, 2023: https://www.renmarkfinancial.com/events/renmark-virtual-non-deal-roadshow-nasdaq-nrsn-2023-03-21-110000 

Tuesday, March 28, 2023: https://www.renmarkfinancial.com/events/renmark-virtual-non-deal-roadshow-nasdaq-nrsn-2023-03-28-100000

• To ensure smooth connectivity, please access this link using the latest version of Google Chrome.

About NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.

About Renmark Financial Communications Inc.

Founded in 1999, Renmark Financial Communications Inc. is North America's leading retail investor relations firm.  Employing a strategic and comprehensive mix of exposure tactics; Renmark hosts Virtual Non-Deal Roadshows as well as in-person corporate presentations and maintains daily communications with thousands of brokers and money managers across Canada and the United States. Renmark empowers its publicly-traded clientele to maximize their visibility within the financial community and strengthen their investor audience.

www.renmarkfinancial.com

Logo - https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/neurosense-therapeutics-ltd-to-participate-in-renmarks-virtual-non-deal-roadshow-series-on-tuesday-march-21-and-tuesday-march-28-2023-301771483.html

SOURCE NeuroSense and Renmark Financial Communications Inc.

FAQ

What is the date and time for NeuroSense Therapeutics' Virtual Non-Deal Roadshow on March 21, 2023?

NeuroSense Therapeutics' Virtual Non-Deal Roadshow is scheduled for March 21, 2023, at 11:00 AM PST.

When is the second session of NeuroSense Therapeutics' Virtual Non-Deal Roadshow?

The second session of NeuroSense Therapeutics' Virtual Non-Deal Roadshow will take place on March 28, 2023, at 10:00 AM EST.

Who will present at the NeuroSense Therapeutics Virtual Non-Deal Roadshow?

CEO Alon Ben-Noon and VP Nedira Salzman-Frenkel will present at the NeuroSense Therapeutics Virtual Non-Deal Roadshow.

How can investors register for the NeuroSense Therapeutics Roadshow?

Investors can register for the NeuroSense Therapeutics Roadshow using the links provided in the press release.

What topics will be discussed during the NeuroSense Therapeutics presentations?

The presentations will cover the latest investor presentation, followed by a live Q&A session.

Where can I find a replay of the NeuroSense Therapeutics Roadshow?

Replays of the NeuroSense Therapeutics Roadshow will be available on the company's investor website.